Imunon, Inc. (then Celsion Corporation) — 2017 Form 10-K
Entity and period: The supplied filing is Celsion Corporation’s annual report for the fiscal year ended December 31, 2017, filed March 27, 2018. It is not a quarterly report. The company later became Imunon, Inc.; the filing reports the company under its 2017 name.
Business context
Celsion was a development-stage oncology company with no product sales. Its lead candidate, ThermoDox, was in a Phase III trial (OPTIMA) for primary liver cancer; GEN-1, a DNA-based immunotherapy, was being developed for ovarian cancer. The company relied on external manufacturers and clinical-trial providers and had no sales or marketing capability.
Financial performance and position
| Metric | FY 2017 | FY 2016 |
|---|---|---|
| Licensing revenue | $0.5 million | $0.5 million |
| Research and development expense | $13.1 million | $14.6 million |
| General and administrative expense | $5.9 million | $6.5 million |
| Operating loss | $18.5 million | $20.6 million |
| Net loss | $20.4 million | $22.1 million |
| Net loss attributable to common shareholders | $20.7 million | $22.1 million |
| Net cash used in operating activities | $16.6 million | $18.4 million |
- Revenue was licensing revenue from a Hisun technology-development payment, recognized over the agreement term; the filing says the company did not expect product revenue for the foreseeable future. With no product sales and only limited licensing revenue, product gross margins are not applicable.
- At December 31, 2017, cash and cash equivalents were $11.4 million and short-term investments were $12.7 million, plus $0.05 million of accrued interest. Current assets were $24.3 million, current liabilities $6.2 million, and working capital $18.1 million. At year-end 2016, cash and investments were $4.3 million and working capital was negative $3.9 million.
- Financing provided $36.5 million net cash in 2017, including $17.9 million from stock sales and $21.1 million from warrant exercises, offset by $2.6 million of debt principal payments. The Hercules loan was paid off in June 2017; no notes payable remained at year-end.
- Accumulated deficit was $261.8 million. Stockholders’ equity was $26.7 million, compared with $6.7 million at year-end 2016. Common shares outstanding increased substantially during 2017, including through offerings and warrant exercises.
- The $2.5 million 2017 in-process research and development impairment and $0.6 million earn-out liability benefit were non-cash items. The filing also recorded a $0.35 million deemed dividend related to warrant modifications.
Material changes and developments
- Net loss narrowed by $1.7 million year over year, while operating expenses fell by $2.2 million. R&D spending declined overall, although OPTIMA trial costs rose to $6.7 million from $5.6 million as enrollment increased.
- The OPTIMA independent monitoring committee reviewed the first 275 patients in 2017 and recommended that the trial continue as planned. By year-end, about 65 sites in 14 countries had been initiated. This was a continuation recommendation, not a finding of efficacy.
- GEN-1’s Phase Ib OVATION trial reported responses and immune-marker changes in a small patient group. The company filed a Phase I/II protocol for OVATION II, including a planned randomized Phase II study of up to 90 patients. The filing also reports median progression-free survival of 21.4 months for 13 treated patients as of March 15, 2018; this is post-year-end, early-stage data and not a controlled efficacy result.
- The company partially impaired its GBM-related acquired R&D asset by $2.5 million, citing competitors’ progress and prioritization of liver and ovarian programs. The related earn-out liability was reduced.
- The company completed a 14-for-1 reverse stock split in May 2017 and raised substantial equity capital through public and registered offerings, warrant exercises and at-the-market sales.
Outlook, risks and contingencies
- Management estimated that December 31, 2017 resources would fund operations into the third quarter of 2019. The company stated it would need additional funding to continue development and operations; apart from its ATM facility, it had no committed financing source. The filing disclosed approximately $13.5 million available under the ATM at year-end and about $12.2 million remaining as of the filing date after subsequent sales.
- ThermoDox’s earlier 701-patient HEAT Phase III trial failed its primary progression-free-survival endpoint. The company’s rationale for OPTIMA relies in part on post-hoc subgroup analyses of overall survival, which the filing cautions should be viewed carefully. OPTIMA’s outcome remained uncertain.
- The DIGNITY breast-cancer program was suspended to focus resources on nearer-term opportunities. The company had no product revenue, expected continued losses, and depended on successful trials, regulatory approvals and future financing.
- Key risks include clinical and regulatory failure or delay, dilution from future equity financing, dependence on third-party manufacturers and trial operators, competition, intellectual-property challenges, and uncertain commercialization and reimbursement. Potential EGEN milestone payments were valued at $12.5 million at year-end; up to $24.4 million could become payable upon specified development milestones, potentially in cash, shares or both.
- The filing reported effective disclosure controls and management’s conclusion that internal control over financial reporting was effective as of December 31, 2017. The 2016 auditor’s report had cited substantial doubt about going concern; the 2017 auditor issued an unmodified financial-statement opinion, while the company continued to disclose its need for future funding.
Most important facts for investors to verify
- OPTIMA enrollment status, protocol execution, interim-review disclosures and final overall-survival results; distinguish prospective trial evidence from HEAT post-hoc subgroup findings.
- Actual cash burn and financing runway, ATM usage, future financing needs, and the dilution or warrant overhang from issued and outstanding securities.
- Whether OVATION II proceeds, its design and enrollment, and whether its results confirm the small OVATION study’s early signals.
- Further impairment testing, the assumptions underlying the $12.5 million EGEN earn-out liability, and any milestones that could trigger payment.
- Any subsequent regulatory, manufacturing, clinical-site, auditor or liquidity developments not reflected in the December 31, 2017 financial statements.